{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T14:52:04Z","timestamp":1763218324180,"version":"3.45.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,15]]},"DOI":"10.7759\/cureus.96909","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T14:49:58Z","timestamp":1763218198000},"source":"Crossref","is-referenced-by-count":0,"title":["Recurrent Nasopharyngeal Chordoma Stabilized With Afatinib: A Case Report"],"prefix":"10.7759","author":[{"given":"Christopher C","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0258-RA","article-title":"Chordoma: a review and differential diagnosis","volume":"146","author":"Ulici V","year":"2022","unstructured":"Ulici V, Hart J. Chordoma: a review and differential diagnosis. Arch Pathol Lab Med. 2022, 146:386-95. 10.5858\/arpa.2020-0258-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3171\/2010.10.SPINE10189","article-title":"Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003","volume":"14","author":"Mukherjee D","year":"2011","unstructured":"Mukherjee D, Chaichana KL, Gokaslan ZL, et al.. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003. J Neurosurg Spine. 2011, 14:143-50. 10.3171\/2010.10.SPINE10189","journal-title":"J Neurosurg Spine"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpr.2022.300624","article-title":"Poorly differentiated chordoma","volume":"28","author":"Yang L","year":"2022","unstructured":"Yang L, Liu Y, Tang Y, et al.. Poorly differentiated chordoma. Hum Pathol Rep. 2022, 28:10.1016\/j.hpr.2022.300624","journal-title":"Hum Pathol Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000209828.39477.ab","article-title":"Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases","volume":"30","author":"Hoch BL","year":"2006","unstructured":"Hoch BL, Nielsen GP, Liebsch NJ, Rosenberg AE. Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases. Am J Surg Pathol. 2006, 30:811-8. 10.1097\/01.pas.0000209828.39477.ab","journal-title":"Am J Surg Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nec.2015.03.012","article-title":"Chordomas: a review","volume":"26","author":"George B","year":"2015","unstructured":"George B, Bresson D, Herman P, Froelich S. Chordomas: a review. Neurosurg Clin N Am. 2015, 26:437-52. 10.1016\/j.nec.2015.03.012","journal-title":"Neurosurg Clin N Am"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051054","article-title":"Chordoma - current understanding and modern treatment paradigms","volume":"10","author":"Barber SM","year":"2021","unstructured":"Barber SM, Sadrameli SS, Lee JJ, et al.. Chordoma - current understanding and modern treatment paradigms. J Clin Med. 2021, 10:10.3390\/jcm10051054","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.038","article-title":"Imatinib in advanced chordoma: a retrospective case series analysis","volume":"51","author":"Hindi N","year":"2015","unstructured":"Hindi N, Casali PG, Morosi C, et al.. Imatinib in advanced chordoma: a retrospective case series analysis. Eur J Cancer. 2015, 51:2609-14. 10.1016\/j.ejca.2015.07.038","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.918927","article-title":"Chordoma: a case report and review of literature","volume":"21","author":"Noor A","year":"2020","unstructured":"Noor A, Bindal P, Ramirez M, Vredenburgh J. Chordoma: a case report and review of literature. Am J Case Rep. 2020, 21:10.12659\/AJCR.918927","journal-title":"Am J Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.06.038","article-title":"Medical treatment of advanced chordomas","volume":"83","author":"Colia V","year":"2017","unstructured":"Colia V, Stacchiotti S. Medical treatment of advanced chordomas. Eur J Cancer. 2017, 83:220-8. 10.1016\/j.ejca.2017.06.038","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.3656","article-title":"Phase II study of imatinib in advanced chordoma","volume":"30","author":"Stacchiotti S","year":"2012","unstructured":"Stacchiotti S, Longhi A, Ferraresi V, et al.. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012, 30:914-20. 10.1200\/JCO.2011.35.3656","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30379","article-title":"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor","volume":"123","author":"Schuetze SM","year":"2017","unstructured":"Schuetze SM, Bolejack V, Choy E, et al.. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017, 123:90-7. 10.1002\/cncr.30379","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0324","article-title":"Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and brachyury","volume":"17","author":"Magnaghi P","year":"2018","unstructured":"Magnaghi P, Salom B, Cozzi L, et al.. Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and brachyury. Mol Cancer Ther. 2018, 17:603-13. 10.1158\/1535-7163.MCT-17-0324","journal-title":"Mol Cancer Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3171\/2011.5.JNS11185","article-title":"Generation of chordoma cell line JHC7 and the identification of brachyury as a novel molecular target","volume":"115","author":"Hsu W","year":"2011","unstructured":"Hsu W, Mohyeldin A, Shah SR, et al.. Generation of chordoma cell line JHC7 and the identification of brachyury as a novel molecular target. J Neurosurg. 2011, 115:760-9. 10.3171\/2011.5.JNS11185","journal-title":"J Neurosurg"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3171\/2016.12.JNS161444","article-title":"Brachyury gene copy number gain and activation of the PI3K\/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma","volume":"128","author":"Otani R","year":"2018","unstructured":"Otani R, Mukasa A, Shin M, et al.. Brachyury gene copy number gain and activation of the PI3K\/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma. J Neurosurg. 2018, 128:1428-37. 10.3171\/2016.12.JNS161444","journal-title":"J Neurosurg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13720","article-title":"Randomized, double\u2010blind, placebo\u2010controlled phase II study of yeast\u2010Brachyury vaccine (GI\u20106301) in combination with standard\u2010of\u2010care radiotherapy in locally advanced, unresectable chordoma","volume":"26","author":"DeMaria PJ","year":"2021","unstructured":"DeMaria PJ, Bilusic M, Park DM, et al.. Randomized, double\u2010blind, placebo\u2010controlled phase II study of yeast\u2010Brachyury vaccine (GI\u20106301) in combination with standard\u2010of\u2010care radiotherapy in locally advanced, unresectable chordoma. Oncologist. 2021, 26:847-58. 10.1002\/onco.13720","journal-title":"Oncologist"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.11517","article-title":"A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma","volume":"42","author":"Lipplaa A","year":"2024","unstructured":"Lipplaa A, Strauss S, Stacchiotti S, et al.. A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma. J Clin Oncol. 2024, 42:10.1200\/JCO.2024.42.16_suppl.11517","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.551160","article-title":"Analysis of the EGFR amplification and CDKN2A deletion regulated transcriptomic signatures reveals the prognostic significance of SPATS2L in patients with glioma","volume":"11","author":"Wang H","year":"2021","unstructured":"Wang H, Wang X, Xu L, et al.. Analysis of the EGFR amplification and CDKN2A deletion regulated transcriptomic signatures reveals the prognostic significance of SPATS2L in patients with glioma. Front Oncol. 2021, 11:10.3389\/fonc.2021.551160","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/426163-recurrent-nasopharyngeal-chordoma-stabilized-with-afatinib-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T14:49:58Z","timestamp":1763218198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/426163-recurrent-nasopharyngeal-chordoma-stabilized-with-afatinib-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.96909","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,15]]}}}